混合供者非植入性扩增祖细胞在单份脐血移植中的安全性与临床结局
这项单中心II期试验纳入28例血液恶性肿瘤患者,在清髓性预处理后接受单份脐血移植并输注目标剂量800×10^6 CD34+细胞的dilanubicel。所有患者中性粒细胞和血小板均植入,无3-4级急慢性GVHD,中位随访1.4年时27例无病生存。
要点
- dilanubicel联合单份脐血移植未观察到3-4级急慢性GVHD。
- 中性粒细胞中位植入18天,血小板中位植入31天。
- 中位随访1.4年,27/28例患者无病生存。
核心结论
- dilanubicel加入单份脐血移植安全性良好,无严重急慢性GVHD,临床结局优异,支持进一步研究。
研究设计与样本
- 单中心II期试验,2022年3月至2025年7月纳入28例血液恶性肿瘤患者。
- 所有患者接受清髓性预处理及环孢素联合吗替麦考酚酯GVHD预防。
主要发现
- 所有患者中性粒细胞植入,中位18天(范围14-30天);血小板植入中位31天(范围26-43天)。
- dilanubicel诱导短暂髓单核细胞恢复,第7天达峰,第14天消失。
- 第9天出现仅源于脐血移植物早期淋巴细胞扩增,第11天达峰。
- 未观察到3-4级急性或慢性GVHD。
- 中位随访1.4年,27例患者存活且无病。
关键数值与推荐
- dilanubicel目标剂量为800×10^6 CD34+细胞。
- 与同期机构队列接受标准单份或双份脐血移植相比,dilanubicel组造血恢复更快且严重急性GVHD发生率显著更低。
临床怎么用
- 在单份脐血移植中加入dilanubicel可促进造血恢复并降低严重GVHD风险,但需进一步研究验证。
局限性
- 单中心、小样本II期试验,与同期队列比较非随机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cord blood transplantation (CBT) is limited by delayed hematopoietic recovery leading to frequent use of double-unit grafts. This phase II study evaluated the safety of adding dilanubicel, a cryopreserved, cord blood (CB)-derived, non-human leukocyte antigen-matched expanded progenitor cell product generated from pooled donors to single-unit CBT. MATERIALS AND METHODS: Between March 2022 and July 2025, we enrolled 28 patients with hematologic malignancies in this single-center phase II trial. The infusion of a matched single CB unit was followed by a target dose of 800 × 106 CD34+ cells of dilanubicel. All patients received a myeloablative conditioning regimen and graft-versus-host disease (GVHD) prophylaxis consisting of cyclosporine and mycophenolate mofetil. RESULTS: The median age was 36 years (range, 10-63). Underlying diagnoses included acute leukemias (n = 25) and other hematologic malignancies (n = 3). All patients engrafted neutrophils (median, 18 days; range, 14-30) and platelets (median, 31 days; range, 26-43). Dilanubicel induced transient myelomonocytic recovery, peaking on day 7 and absent by day 14. An early lymphocyte expansion, derived exclusively from the CB graft, occurred by day 9 and peaked by day 11. No grade 3 to 4 acute or chronic GVHD was observed. At a median follow-up of 1.4 years, 27 patients remain alive and disease-free. When evaluated alongside a contemporaneous institutional cohort receiving standard single- or double-unit CBT, patients treated with dilanubicel demonstrated faster hematopoietic recovery and a markedly lower incidence of severe acute GVHD. CONCLUSION: The addition of dilanubicel to single-unit CBT demonstrated a favorable safety profile, with no severe acute or chronic GVHD, and was associated with excellent clinical outcomes. These findings support further investigation of this strategy.
引用
- Milano F, Dahlberg A, Pedersen J, et al. Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation. J Clin Oncol. 2026. PMID: 42044462. doi:10.1200/JCO-25-02510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。